Kelce did little to shut down speculation during the lead-up to Super Bowl 2025 that he could retire after the last game and ...
The response from the Titans, Browns, Giants and Patriots — or any other team that trades into a top four pick — to the idea ...
Compounding pharmacies aren’t surrendering their ability to create cheaper knockoff versions of Eli Lilly and Novo Nordisk’s ...
Don’t add Kirk Cousins’ name to the list of free-agent quarterbacks just yet. Falcons general manager Terry Fontenot ...
Revenues in the biopharma industry continued to boom in the fourth quarter of last year, following a pattern seen ...
Tanner Engstrand’s job is with the Jets as the most important hire made by new head coach Aaron Glenn, especially as the ...
The college football overtime rule stinks. It’s so confusing that casual football fans still are surprised to hear how it ...
There is a catch. If the private equity firms can boost sales of bluebird’s three gene therapies to $600 million—over any ...
Bristol Myers Squibb has bolstered its case for Opdivo to be used as a pre-operative treatment for non-small cell lung cancer ...
Judging from its top line, AstraZeneca had a stellar 2024, generating an 18% increase in revenue, with 14 of the products in ...
Challenging powerhouse Pfizer, BridgeBio's launch of Attruby is off to a 'great start,' analyst says
An intriguing battle is brewing in the market to treat patients with transthyretin amyloid cardiomyopathy (ATTR-CM). | BridgeBio reported that 1,028 unique prescriptions have been written by 516 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results